{"id":"tolterodine-6","safety":{"commonSideEffects":[{"rate":"35-40","effect":"Dry mouth"},{"rate":"5-7","effect":"Headache"},{"rate":"10-15","effect":"Constipation"},{"rate":"2-4","effect":"Dizziness"},{"rate":"1-2","effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL1722209","moleculeType":"Small molecule","molecularWeight":"475.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tolterodine selectively antagonizes M2 and M3 muscarinic receptors in the detrusor muscle of the bladder. By blocking these receptors, it prevents acetylcholine-induced bladder contractions, thereby increasing bladder capacity and reducing the frequency of micturition and urgency episodes associated with overactive bladder.","oneSentence":"Tolterodine is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:06.529Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT05658874","phase":"PHASE3","title":"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jocelyn Fitzgerald","startDate":"2022-12-01","conditions":"Interstitial Cystitis","enrollment":26},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":"Urinary Incontinence, Urgency Urinary","enrollment":20},{"nctId":"NCT04500860","phase":"PHASE1","title":"Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2020-12-01","conditions":"Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence","enrollment":90},{"nctId":"NCT00730535","phase":"PHASE4","title":"Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients","status":"COMPLETED","sponsor":"KYU-SUNG LEE","startDate":"2006-08","conditions":"Overactive Bladder","enrollment":173},{"nctId":"NCT00465894","phase":"NA","title":"Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-04","conditions":"Overactive Bladder","enrollment":58},{"nctId":"NCT03662893","phase":"NA","title":"Behavioural Therapy With Checklist for Overactive Bladder","status":"COMPLETED","sponsor":"Ankara Training and Research Hospital","startDate":"2015-01-01","conditions":"Overactive Bladder","enrollment":120},{"nctId":"NCT02176642","phase":"PHASE4","title":"Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.","status":"TERMINATED","sponsor":"Duke University","startDate":"2014-08","conditions":"Urinary Urge Incontinence","enrollment":55},{"nctId":"NCT02723279","phase":"NA","title":"Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women","status":"COMPLETED","sponsor":"Shanghai Institute of Acupuncture, Moxibustion and Meridian","startDate":"2016-04","conditions":"Urgency-frequency Syndrome","enrollment":120},{"nctId":"NCT01175382","phase":"PHASE2, PHASE3","title":"Combined Behavioral and Drug Treatment of Overactive Bladder in Men","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2010-07","conditions":"Overactive Bladder, Lower Urinary Tract Symptoms","enrollment":204},{"nctId":"NCT00498888","phase":"NA","title":"The Long Term Outcomes of Rehabilitation and Drug Treatment for in Urgency Urinary Incontinence","status":"COMPLETED","sponsor":"Assuta Hospital Systems","startDate":"2007-06","conditions":"Urge Urinary Incontinence","enrollment":164}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":325,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Detrusitol ER 4mg"],"phase":"marketed","status":"active","brandName":"Tolterodine 6","genericName":"Tolterodine 6","companyName":"KYU-SUNG LEE","companyId":"kyu-sung-lee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tolterodine is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}